Advertisement

Systematic review for the 2017 AHA/ACC/HRS guideline for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death

A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society
Published:October 30, 2017DOI:https://doi.org/10.1016/j.hrthm.2017.10.037

      Background

      Although large randomized clinical trials have found that primary prevention use of an implantable cardioverter-defibrillator (ICD) improves survival in patients with cardiomyopathy and heart failure symptoms, patients who receive ICDs in practice are often older and have more comorbidities than patients who were enrolled in the clinical trials. In addition, there is a debate among clinicians on the usefulness of electrophysiological study for risk stratification of asymptomatic patients with Brugada syndrome.

      Aim

      Our analysis has 2 objectives. First, to evaluate whether ventricular arrhythmias (VAs) induced with programmed electrostimulation in asymptomatic patients with Brugada syndrome identify a higher risk group that may require additional testing or therapies. Second, to evaluate whether implantation of an ICD is associated with a clinical benefit in older patients and patients with comorbidities who would otherwise benefit on the basis of left ventricular ejection fraction and heart failure symptoms.

      Methods

      Traditional statistical approaches were used to address 1) whether programmed ventricular stimulation identifies a higher-risk group in asymptomatic patients with Brugada syndrome and 2) whether ICD implantation for primary prevention is associated with improved outcomes in older patients (>75 years of age) and patients with significant comorbidities who would otherwise meet criteria for ICD implantation on the basis of symptoms or left ventricular function.

      Results

      Evidence from 6 studies of 1138 asymptomatic patients were identified. Brugada syndrome with inducible VA on electrophysiological study was identified in 390 (34.3%) patients. To minimize patient overlap, the primary analysis used 5 of the 6 studies and found an odds ratio of 2.3 (95% CI: 0.63–8.66; p=0.2) for major arrhythmic events (sustained VAs, sudden cardiac death, or appropriate ICD therapy) in asymptomatic patients with Brugada syndrome and inducible VA on electrophysiological study versus those without inducible VA.
      Ten studies were reviewed that evaluated ICD use in older patients and 4 studies that evaluated unique patient populations were identified. In our analysis, ICD implantation was associated with improved survival (overall hazard ratio: 0.75; 95% confidence interval: 0.67–0.83; p<0.001). Ten studies were identified that evaluated ICD use in patients with various comorbidities including renal disease, chronic obstructive pulmonary disease, atrial fibrillation, heart disease, and others. A random effects model demonstrated that ICD use was associated with reduced all-cause mortality (overall hazard ratio: 0.72; 95% confidence interval: 0.65–0.79; p<0.0001), and a second “minimal overlap” analysis also found that ICD use was associated with reduced all-cause mortality (overall hazard ratio: 0.71; 95% confidence interval: 0.61–0.82; p<0.0001). In 5 studies that included data on renal dysfunction, ICD implantation was associated with reduced all-cause mortality (overall hazard ratio: 0.71; 95% confidence interval: 0.60–0.85; p<0.001).

      Keywords

      To read this article in full you will need to make a payment

      Subscribe:

      Subscribe to Heart Rhythm
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Committee on Standards for Developing Trustworthy Clinical Practice Guidelines
        • Institute of Medicine (U.S.)
        Clinical Practice Guidelines We Can Trust.
        National Academies Press, Washington, DC2011
        • Committee on Standards for Systematic Reviews of Comparative Effectiveness Research
        • Institute of Medicine (U.S.)
        Finding What Works in Health Care: Standards for Systematic Reviews.
        National Academies Press, Washington, DC2011
        • ACCF/AHA Task Force on Practice Guidelines
        Methodology Manual and Policies From the ACCF/AHA Task Force on Practice Guidelines.
        American College of Cardiology and American Heart Association. 2010; (Available at:) (and) (Accessed October 1, 2017)
        • Halperin J.L.
        • Levine G.N.
        • Al-Khatib S.M.
        • et al.
        Further evolution of the ACC/AHA clinical practice guideline recommendation classification system: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Clinical Practice Guidelines.
        J Am Coll Cardiol. 2016; 67: 1572-1574
        • Jacobs A.K.
        • Kushner F.G.
        • Ettinger S.M.
        • et al.
        ACCF/AHA clinical practice guideline methodology summit report: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines.
        J Am Coll Cardiol. 2013; 61: 213-265
        • Jacobs A.K.
        • Anderson J.L.
        • Halperin J.L.
        The evolution and future of ACC/AHA clinical practice guidelines: a 30-year journey: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines.
        J Am Coll Cardiol. 2014; 64: 1373-1384
        • Brugada P.
        • Brugada J.
        Right bundle branch block, persistent ST segment elevation and sudden cardiac death: a distinct clinical and electrocardiographic syndrome. A multicenter report.
        J Am Coll Cardiol. 1992; 20: 1391-1396
        • Priori S.G.
        • Wilde A.A.
        • Horie M.
        • et al.
        HRS/EHRA/APHRS expert consensus statement on the diagnosis and management of patients with inherited primary arrhythmia syndromes: document endorsed by HRS, EHRA, and APHRS in May 2013 and by ACCF, AHA, PACES, and AEPC in June 2013.
        Heart Rhythm. 2013; 10: 1932-1963
        • Brugada P.
        • Geelen P.
        • Brugada R.
        • et al.
        Prognostic value of electrophysiologic investigations in Brugada syndrome.
        J Cardiovasc Electrophysiol. 2001; 12: 1004-1007
        • Brugada P.
        • Brugada R.
        • Mont L.
        • et al.
        Natural history of Brugada syndrome: the prognostic value of programmed electrical stimulation of the heart.
        J Cardiovasc Electrophysiol. 2003; 14: 455-457
        • Kamakura S.
        • Ohe T.
        • Nakazawa K.
        • et al.
        Long-term prognosis of probands with Brugada-pattern ST-elevation in leads V1-V3.
        Circ Arrhythm Electrophysiol. 2009; 2: 495-503
        • Priori S.G.
        • Gasparini M.
        • Napolitano C.
        • et al.
        Risk stratification in Brugada syndrome: results of the PRELUDE (PRogrammed ELectrical stimUlation preDictive valuE) registry.
        J Am Coll Cardiol. 2012; 59: 37-45
        • Priori S.G.
        • Napolitano C.
        • Gasparini M.
        • et al.
        Clinical and genetic heterogeneity of right bundle branch block and ST-segment elevation syndrome: a prospective evaluation of 52 families.
        Circulation. 2000; 102: 2509-2515
        • Probst V.
        • Veltmann C.
        • Eckardt L.
        • et al.
        Long-term prognosis of patients diagnosed with Brugada syndrome: results from the FINGER Brugada Syndrome Registry.
        Circulation. 2010; 121: 635-643
        • Sieira J.
        • Ciconte G.
        • Conte G.
        • et al.
        Asymptomatic Brugada syndrome: clinical characterization and long-term prognosis.
        Circ Arrhythm Electrophysiol. 2015; 8: 1144-1150
        • Takagi M.
        • Yokoyama Y.
        • Aonuma K.
        • et al.
        Clinical characteristics and risk stratification in symptomatic and asymptomatic patients with Brugada syndrome: multicenter study in Japan.
        J Cardiovasc Electrophysiol. 2007; 18: 1244-1251
        • van Rees J.B.
        • de Bie M.K.
        • Thijssen J.
        • et al.
        Implantation-related complications of implantable cardioverter-defibrillators and cardiac resynchronization therapy devices: a systematic review of randomized clinical trials.
        J Am Coll Cardiol. 2011; 58: 995-1000
        • Ackerman M.J.
        • DeSimone C.V.
        Programmed electrical stimulation for patients with asymptomatic Brugada syndrome? The shock-filled debate continues.
        J Am Coll Cardiol. 2015; 65: 889-891
        • Eckardt L.
        • Probst V.
        • Smits J.P.
        • et al.
        Long-term prognosis of individuals with right precordial ST-segment-elevation Brugada syndrome.
        Circulation. 2005; 111: 257-263
        • Conte G.
        • Sieira J.
        • Ciconte G.
        • et al.
        Implantable cardioverter-defibrillator therapy in Brugada syndrome: a 20-year single-center experience.
        J Am Coll Cardiol. 2015; 65: 879-888
        • Sacher F.
        • Probst V.
        • Maury P.
        • et al.
        Outcome after implantation of a cardioverter-defibrillator in patients with Brugada syndrome: a multicenter study-part 2.
        Circulation. 2013; 128: 1739-1747
        • Priori S.G.
        • Blomstrom-Lundqvist C.
        • Mazzanti A.
        • et al.
        2015 ESC guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: the Task Force for the Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death of the European Society of Cardiology (ESC). Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC).
        Europace. 2015; 17: 1601-1687
        • Sieira J.
        • Conte G.
        • Ciconte G.
        • et al.
        Prognostic value of programmed electrical stimulation in Brugada syndrome: 20 years experience.
        Circ Arrhythm Electrophysiol. 2015; 8: 777-784
        • Makimoto H.
        • Kamakura S.
        • Aihara N.
        • et al.
        Clinical impact of the number of extrastimuli in programmed electrical stimulation in patients with Brugada type 1 electrocardiogram.
        Heart Rhythm. 2012; 9: 242-248
        • Bardy G.H.
        • Lee K.L.
        • Mark D.B.
        • et al.
        Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure.
        N Engl J Med. 2005; 352: 225-237
        • Moss A.J.
        • Hall W.J.
        • Cannom D.S.
        • et al.
        Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. Multicenter Automatic Defibrillator Implantation Trial Investigators.
        N Engl J Med. 1996; 335: 1933-1940
        • Moss A.J.
        • Zareba W.
        • Hall W.J.
        • et al.
        Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction.
        N Engl J Med. 2002; 346: 877-883
        • Buxton A.E.
        • Lee K.L.
        • Fisher J.D.
        • et al.
        A randomized study of the prevention of sudden death in patients with coronary artery disease. Multicenter Unsustained Tachycardia Trial Investigators.
        N Engl J Med. 1999; 341: 1882-1890
        • Kadish A.
        • Dyer A.
        • Daubert J.P.
        • et al.
        Prophylactic defibrillator implantation in patients with nonischemic dilated cardiomyopathy.
        N Engl J Med. 2004; 350: 2151-2158
        • Steinbeck G.
        • Andresen D.
        • Seidl K.
        • et al.
        Defibrillator implantation early after myocardial infarction.
        N Engl J Med. 2009; 361: 1427-1436
        • Kusumoto F.M.
        • Calkins H.
        • Boehmer J.
        • et al.
        HRS/ACC/AHA expert consensus statement on the use of implantable cardioverter-defibrillator therapy in patients who are not included or not well represented in clinical trials.
        Heart Rhythm. 2014; 11: 1271-1303
        • Zipes D.P.
        • Camm A.J.
        • Borggrefe M.
        • et al.
        ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: a report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death). Developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society.
        Circulation. 2006; 114: e385-e484
        • Lambiase P.D.
        • Barr C.
        • Theuns D.A.
        • et al.
        Worldwide experience with a totally subcutaneous implantable defibrillator: early results from the EFFORTLESS S-ICD Registry.
        Eur Heart J. 2014; 35: 1657-1665
        • Weiss R.
        • Knight B.P.
        • Gold M.R.
        • et al.
        Safety and efficacy of a totally subcutaneous implantable-cardioverter defibrillator.
        Circulation. 2013; 128: 944-953
        • Mond H.G.
        • Proclemer A.
        The 11th world survey of cardiac pacing and implantable cardioverter-defibrillators: calendar year 2009–a World Society of Arrhythmia’s project.
        Pacing Clin Electrophysiol. 2011; 34: 1013-1027
        • Bigger Jr., J.T.
        Prophylactic use of implanted cardiac defibrillators in patients at high risk for ventricular arrhythmias after coronary-artery bypass graft surgery. Coronary Artery Bypass Graft (CABG) Patch Trial Investigators.
        N Engl J Med. 1997; 337: 1569-1575
        • Hohnloser S.H.
        • Kuck K.H.
        • Dorian P.
        • et al.
        Prophylactic use of an implantable cardioverter-defibrillator after acute myocardial infarction.
        N Engl J Med. 2004; 351: 2481-2488
        • Kong M.H.
        • Al-Khatib S.M.
        • Sanders G.D.
        • et al.
        Use of implantable cardioverter-defibrillators for primary prevention in older patients: a systematic literature review and meta-analysis.
        Cardiol J. 2011; 18: 503-514
        • Kramer D.B.
        • Kennedy K.F.
        • Noseworthy P.A.
        • et al.
        Characteristics and outcomes of patients receiving new and replacement implantable cardioverter-defibrillators: results from the NCDR.
        Circ Cardiovasc Qual Outcomes. 2013; 6: 488-497
        • Charlson M.E.
        • Pompei P.
        • Ales K.L.
        • et al.
        A new method of classifying prognostic comorbidity in longitudinal studies: development and validation.
        J Chronic Dis. 1987; 40: 373-383
        • Elixhauser A.
        • Steiner C.
        • Harris D.R.
        • et al.
        Comorbidity measures for use with administrative data.
        Med Care. 1998; 36: 8-27
        • Al-Khatib S.M.
        • Hellkamp A.S.
        • Fonarow G.C.
        • et al.
        Association between prophylactic implantable cardioverter-defibrillators and survival in patients with left ventricular ejection fraction between 30% and 35%.
        JAMA. 2014; 311: 2209-2215
        • Goldenberg I.
        • Moss A.J.
        • McNitt S.
        • et al.
        Relations among renal function, risk of sudden cardiac death, and benefit of the implanted cardiac defibrillator in patients with ischemic left ventricular dysfunction.
        Am J Cardiol. 2006; 98: 485-490
        • Hernandez A.F.
        • Fonarow G.C.
        • Hammill B.G.
        • et al.
        Clinical effectiveness of implantable cardioverter-defibrillators among medicare beneficiaries with heart failure.
        Circ Heart Fail. 2010; 3: 7-13
        • Hess P.L.
        • Al-Khatib S.M.
        • Han J.Y.
        • et al.
        Survival benefit of the primary prevention implantable cardioverter-defibrillator among older patients: does age matter? An analysis of pooled data from 5 clinical trials.
        Circ Cardiovasc Qual Outcomes. 2015; 8: 179-186
        • Hiremath S.
        • Punnam S.R.
        • Brar S.S.
        • et al.
        Implantable defibrillators improve survival in end-stage renal disease: results from a multi-center registry.
        Am J Nephrol. 2010; 32: 305-310
        • Huang D.T.
        • Sesselberg H.W.
        • McNitt S.
        • et al.
        Improved survival associated with prophylactic implantable defibrillators in elderly patients with prior myocardial infarction and depressed ventricular function: a MADIT-II substudy.
        J Cardiovasc Electrophysiol. 2007; 18: 833-838
        • Khazanie P.
        • Hellkamp A.S.
        • Fonarow G.C.
        • et al.
        Association between comorbidities and outcomes in heart failure patients with and without an implantable cardioverter-defibrillator for primary prevention.
        J Am Heart Assoc. 2015; 4e002061
        • Mezu U.
        • Adelstein E.
        • Jain S.
        • et al.
        Effectiveness of implantable defibrillators in octogenarians and nonagenarians for primary prevention of sudden cardiac death.
        Am J Cardiol. 2011; 108: 718-722
        • Nakhoul G.N.
        • Schold J.D.
        • Arrigain S.
        • et al.
        Implantable cardioverter-defibrillators in patients with CKD: a propensity-matched mortality analysis.
        Clin J Am Soc Nephrol. 2015; 10: 1119-1127
        • Pokorney S.D.
        • Hellkamp A.S.
        • Yancy C.W.
        • et al.
        Primary prevention implantable cardioverter-defibrillators in older racial and ethnic minority patients.
        Circ Arrhythm Electrophysiol. 2015; 8: 145-151
        • Pun P.H.
        • Al-Khatib S.M.
        • Han J.Y.
        • et al.
        Implantable cardioverter-defibrillators for primary prevention of sudden cardiac death in CKD: a meta-analysis of patient-level data from 3 randomized trials.
        Am J Kidney Dis. 2014; 64: 32-39
        • Pun P.H.
        • Hellkamp A.S.
        • Sanders G.D.
        • et al.
        Primary prevention implantable cardioverter defibrillators in end-stage kidney disease patients on dialysis: a matched cohort study.
        Nephrol Dial Transplant. 2015; 30: 829-835
        • Razak E.
        • Kamireddy S.
        • Saba S.
        Implantable cardioverter-defibrillators confer survival benefit in patients with chronic obstructive pulmonary disease.
        Pacing Clin Electrophysiol. 2010; 33: 1125-1130
        • Steinberg B.A.
        • Al-Khatib S.M.
        • Edwards R.
        • et al.
        Outcomes of implantable cardioverter-defibrillator use in patients with comorbidities: results from a combined analysis of 4 randomized clinical trials.
        JACC Heart Fail. 2014; 2: 623-629
        • Wittenberg S.M.
        • Cook J.R.
        • Hall W.J.
        • et al.
        Comparison of efficacy of implanted cardioverter-defibrillator in patients with versus without diabetes mellitus.
        Am J Cardiol. 2005; 96: 417-419
        • Zeitler E.P.
        • Hellkamp A.S.
        • Fonarow G.C.
        • et al.
        Primary prevention implantable cardioverter-defibrillators and survival in older women.
        JACC Heart Fail. 2015; 3: 159
        • Zeitler E.P.
        • Hellkamp A.S.
        • Schulte P.J.
        • et al.
        Comparative effectiveness of implantable cardioverter defibrillators for primary prevention in women.
        Circ Heart Fail. 2016; 9e002630
        • Hershberger R.E.
        • Morales A.
        • Siegfried J.D.
        Clinical and genetic issues in dilated cardiomyopathy: a review for genetics professionals.
        Genet Med. 2010; 12: 655-667
      1. Office of the Chief Actuary SSA. Actuarial Life Table. Available at: https://www.ssa.gov/oact/STATS/table4c6.html. Accessed August 26, 2017.

        • Bilchick K.C.
        • Stukenborg G.J.
        • Kamath S.
        • et al.
        Prediction of mortality in clinical practice for medicare patients undergoing defibrillator implantation for primary prevention of sudden cardiac death.
        J Am Coll Cardiol. 2012; 60: 1647-1655
        • Goldenberg I.
        • Vyas A.K.
        • Hall W.J.
        • et al.
        Risk stratification for primary implantation of a cardioverter-defibrillator in patients with ischemic left ventricular dysfunction.
        J Am Coll Cardiol. 2008; 51: 288-296
        • Buxton A.E.
        Should everyone with an ejection fraction less than or equal to 30% receive an implantable cardioverter-defibrillator? Not everyone with an ejection fraction < or = 30% should receive an implantable cardioverter-defibrillator.
        Circulation. 2005; 111: 2537-2549
        • Kober L.
        • Thune J.J.
        • Nielsen J.C.
        • et al.
        Defibrillator implantation in patients with nonischemic systolic heart failure.
        N Engl J Med. 2016; 375: 1221-1230
        • Setoguchi S.
        • Warner Stevenson L.
        • Stewart G.C.
        • et al.
        Influence of healthy candidate bias in assessing clinical effectiveness for implantable cardioverter-defibrillators: cohort study of older patients with heart failure.
        BMJ. 2014; 348: g2866
        • Amin M.S.
        • Fox A.D.
        • Kalahasty G.
        • et al.
        Benefit of primary prevention implantable cardioverter-defibrillators in the setting of chronic kidney disease: a decision model analysis.
        J Cardiovasc Electrophysiol. 2008; 19: 1275-1280
        • Bloomfield E.L.
        • Kauten J.
        • Ocampo M.
        • et al.
        A decision support model for prescribing internal cardiac defibrillators.
        Int J Health Care Qual Assur. 2013; 26: 455-464
        • Prasad V.
        • Jena A.B.
        Prespecified falsification end points: can they validate true observational associations?.
        JAMA. 2013; 309: 241-242

      Linked Article

      • Correction
        Heart RhythmVol. 15Issue 11
        • Preview
          In the article by Kusumoto et al, “Systematic review for the 2017 AHA/ACC/HRS guideline for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society,” which published ahead of print on October 30, 2017, and appeared in the October 2018 issue of the journal (Heart Rhythm 2018;15:e253–e274. DOI: https://doi.org/10.1016/j.hrthm.2017.10.037 ), several corrections were made during the proofing stage and are outlined below.
        • Full-Text
        • PDF